Bristol-Myers Squibb (NYSE:BMY) generates its revenues from its Oncology, Cardiovascular, Immunology, Virology, along with its Mature Drugs & Other segment. Oncology accounts for over 40% of the company's total revenues, and will likely see steady growth in the coming years, led by a ramp up...
Bristol-Myers Squibb (NYSE:BMY) generates its revenues from its Oncology, Cardiovascular, Immunology, Virology, along with its Mature Drugs & Other segment. Oncology accounts for over 40% of the company's total revenues, and will likely see steady growth in the coming years, led by a ramp up...
Share this Article
Recommended